Epistem’s Biomarker Focus in the US
Epistem’s biomarker collaborations in North America will focus on preclinical and clinical oncology drug development providing a means of translating drug effect in specific oncology pathways such as Hedgehog, WNT, Notch, Beta Catenin, PI3 kinase and androgen signalling as well as providing an ideal platform for evaluating therapies aimed at specific RNA targets. The Biomarker Laboratory services will be delivered within a regulatory framework to comply with Good Clinical Laboratory Practice (GcLP).
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.